We have located links that may give you full text access.
IMPACT OF METFORMIN ON OSTEOPROTEGERIN LEVELS IN POLYCYSTIC OVARIAN WOMEN.
Georgian Medical News 2024 January
Metformin is an important agent in the treatment of polycystic ovary syndrome (PCOS) treatment. Osteoblast express osteoprotegerin (OPG) which has integral effects on bone metabolism nexus. This cross-sectional research sought to identify the impact of metformin therapy on serum level osteoblast express osteoprotegerin and prolactin in women with polycystic ovary syndrome. Methods: 30 patients with PCOS and 30 controls. The current study revealed that prolactin levels were increased in PCOS group compared to control group which is highly significant. While after treatment with metformin prolactin level was reduced significantly in than before treatment. Osteoprotegerin concentrations were considerably dropped in the PCOS group contrasted with the control group. Conversely, serum osteoprotegerin in metformin-treated group were higher compared to PCOS group. Osteoblast express osteoprotegerin level increased after 3 months of treatment with metformin in women with polycystic ovary syndrome.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app